S. Mirkin

J. Balasch, S. Mirkin, J. Vanrell, 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms

M. McClung, G. Constantine, R. Kagan, 2020, Menopause.

Factors Associated with an Optimal Pregnancy Outcome in an Oocyte Donation Program

S. Oehninger, S. Mirkin, W. Gibbons, 2003, Journal of Assisted Reproduction and Genetics.

Gene expression profiles and structural/functional features of the peri-implantation endometrium in natural and gonadotropin-stimulated cycles.

Jose I. Diaz, S. Oehninger, S. Mirkin, 2004, The Journal of clinical endocrinology and metabolism.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women

J. Reginster, J. Jansen, S. Sutradhar, 2014, Current medical research and opinion.

Human vaginal pH and microbiota: an update

D. Archer, S. Mirkin, Keshav Godha, 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women

D. Archer, S. Mirkin, Keshav Godha, 2018, Menopause.

Long-Lasting, Patient-Controlled, Procedure-Free Contraception: A Review of Annovera with a Pharmacist Perspective

S. Mirkin, Christiane E. Carney, K. Besinque, 2020, Pharmacy.

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review

K. Lapane, G. Constantine, S. Mirkin, 2019, Menopause.

A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause

S. Mirkin, Colton Biehl, Olivia Plotsker, 2019, Menopause.

The Women's EMPOWER Survey: Women's Knowledge and Awareness of Treatment Options for Vulvar and Vaginal Atrophy Remains Inadequate.

S. Mirkin, S. Kingsberg, M. Krychman, 2017, The journal of sexual medicine.

Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells.

D. Archer, S. Mirkin, 2004, Fertility and sterility.

An overview of current and emerging SERMs

B. Komm, S. Mirkin, 2014, The Journal of Steroid Biochemistry and Molecular Biology.

Effect of 17β-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells

D. Archer, S. Mirkin, B. C. Wong, 2005 .

A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture

Jacques P. Brown, S. Silverman, A. Chines, 2015, Menopause.

Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-α mRNA in Ishikawa cells

D. Archer, S. Mirkin, 2007 .

Uterine bleeding with hormone therapies in menopausal women: a systematic review

R. Kagan, D. Archer, S. Mirkin, 2020, Climacteric : the journal of the International Menopause Society.

Conjugated estrogens for the treatment of menopausal symptoms: a review of safety data

B. Komm, S. Mirkin, J. Pickar, 2014, Expert opinion on drug safety.

The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy

B. Komm, S. Mirkin, 2012, Pharmaceuticals.

The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis

S. Mirkin, J. Pickar, 2012, Current Obstetrics and Gynecology Reports.

Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR)∗

D. Archer, S. Mirkin, J. Pickar, 2020, Menopause.

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

G. Constantine, R. Kagan, D. Archer, 2018, Obstetrics and gynecology.

Evidence on the use of progesterone in menopausal hormone therapy

S. Mirkin, 2018, Climacteric : the journal of the International Menopause Society.

Prescribing of FDA-approved and compounded hormone therapy differs by specialty

G. Constantine, D. Archer, S. Mirkin, 2016, Menopause.

A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.

A. Chines, K. Ryan, K. Pan, 2015, The Journal of clinical endocrinology and metabolism.

Segesterone Acetate Serum Levels with a Regression Model of Continuous Use of the Segesterone Acetate/Ethinyl Estradiol Contraceptive Vaginal System.

J. Simon, D. Archer, S. Mirkin, 2021, Contraception.

Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells.

D. Archer, S. Mirkin, Francisco J Navarro, 2004, Fertility and sterility.

Impact of Transabdominal Ultrasound Guidance on Performance and Outcome of Transcervical Uterine Embryo Transfer

S. Oehninger, S. Mirkin, W. Gibbons, 2003, Journal of Assisted Reproduction and Genetics.

Qualitative cross-cultural exploration of breast symptoms and impacts associated with hormonal treatments for menopausal symptoms to inform the development of new patient-reported measurement tools.

L. Dennerstein, T. Symonds, J. Simon, 2015, Maturitas.

Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms

J. Simon, S. Mirkin, A. Kaunitz, 2019, Menopause.

TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.

L. Derogatis, J. Simon, G. Constantine, 2016, The journal of sexual medicine.

Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.

J. Cappelleri, A. Chines, A. Bushmakin, 2014, Journal of women's health.

Breast Effects of Bazedoxifene-Conjugated Estrogens: A Randomized Controlled Trial

A. Chines, J. Harvey, K. Ryan, 2013, Obstetrics and gynecology.

Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens

A. Chines, E. Baracat, J. Harvey, 2012, Menopause.

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone

D. Revicki, G. Constantine, S. Mirkin, 2019, Menopause.

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history

S. Mirkin, S. Kingsberg, M. Krychman, 2018, Menopause.

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women

G. Constantine, D. Archer, C. Bouchard, 2017, Journal of women's health.

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

Gynecologic Safety of Conjugated Estrogens Plus Bazedoxifene: Pooled Analysis of Five Phase 3 Trials.

B. Komm, R. Kagan, D. Archer, 2016, Journal of women's health.

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms

D. Revicki, G. Constantine, R. Kagan, 2019, Menopause.

Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss

B. Komm, S. Mirkin, Simon N Jenkins, 2014, Steroids.

B. Komm, Carolyn L. Smith, R. Santen, 2014, Breast Cancer Research.

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries

H. Currie, G. Constantine, S. Mirkin, 2016, Post reproductive health.

B. Komm, Carolyn L. Smith, R. Santen, 2014, Breast Cancer Research.

Prevalence of menopausal symptoms among mid-life women: findings from electronic medical records

J. Menzin, M. Friedman, J. Trocio, 2015, BMC Women's Health.

Evolution of the tissue selective estrogen complex (TSEC)

B. Komm, S. Mirkin, Barry S. Komm, 2013, Journal of cellular physiology.

Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms

N. Santoro, R. Lobo, S. Mirkin, 2019, Climacteric : the journal of the International Menopause Society.

An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.

E. Freeman, A. Rapkin, G. Constantine, 2012, Contraception.

Hormone therapy and endometrial angiogenesis

D. Archer, S. Mirkin, Francisco J Navarro, 2003, Climacteric : the journal of the International Menopause Society.

A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause

D. Archer, S. Mirkin, B. Bernick, 2019, Expert review of clinical pharmacology.

Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial

S. Mirkin, James H. Liu, L. Larkin, 2020, Menopause.

17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review.

D. Archer, S. Mirkin, J. Pickar, 2015, Maturitas.

Recent advances help understand and improve the safety of menopausal therapies

B. Komm, D. Archer, S. Mirkin, 2015, Menopause.

Effects of 17β-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messengerRNA in breast cancer cells

D. Archer, S. Mirkin, B. C. Wong, 2006 .

Efficacy and tolerability of bazedoxifene in Mexican women with osteoporosis: a subgroup analysis of a randomized phase 3 trial

B. Komm, K. Pan, S. Mirkin, 2016, Menopause.

Conjugated Estrogen/Bazedoxifene Tablets for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated with Menopause

B. Komm, S. Mirkin, J. Pickar, 2014, Women's health.

Effect of conjugated estrogens/bazedoxifene on postmenopausal bone loss: pooled analysis of two randomized trials

B. Komm, J. Gallagher, K. Ryan, 2016, Menopause.

137 EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS ON SLEEP PARAMETERS AND HEALTH-RELATED QUALITY OF LIFE IN POSTMENOPAUSAL WOMEN

A. Chines, K. Pan, S. Mirkin, 2012 .

67 SAFETY AND TOLERABILITY OF BAZEDOXIFENE/CONJUGATED ESTROGENS IN POSTMENOPAUSAL WOMEN: FINDINGS FROM A 1 -YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED, PHASE 3 TRIAL

A. Chines, D. Archer, R. Lobo, 2012 .

68 THE EFFECTS OF BAZEDOXIFENE/CONJUGATED ESTROGENS ON BREAST DENSITY IN POSTMENOPAUSAL WOMEN

A. Chines, J. Harvey, K. Pan, 2012 .

Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy

B. Komm, S. Mirkin, 2012, International journal of women's health.

Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens

J. Cappelleri, A. Bushmakin, S. Mirkin, 2014, Menopause.

Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling

J. Cappelleri, A. Chines, A. Bushmakin, 2014, Menopause.

Genomic and proteomic analyses of the endometrium during the window of implantation following laser capture microdissection: Comparison of natural and controlled ovarian hyperstimulation (COH) cycles

Jose I. Diaz, S. Oehninger, S. Mirkin, 2004 .

In Reply.

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

NEURAL MECHANISMS OF OBESITY The Role of the Focal Adhesion Kinase Family in Leptin Receptor Signaling

S. Mirkin, A. Kaunitz, M. Plagianos, 2020 .

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial

D. Revicki, J. Simon, G. Constantine, 2020, Menopause.

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women

G. Constantine, R. Kagan, S. Mirkin, 2018, Menopause.

Return to fertility after cessation of a continuous oral contraceptive.

K. Barnhart, G. Constantine, S. Mirkin, 2009, Fertility and sterility.

Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials

B. Komm, K. Ryan, S. Mirkin, 2016, Menopause.

013 Product Acceptability and Women's Satisfaction with a Low-dose Solubilized Vaginal Estradiol Softgel Capsule, TX-004H

I. Goldstein, G. Constantine, S. Mirkin, 2017 .

The tissue selective estrogen complex: a promising new menopausal therapy.

B. Komm, S. Mirkin, 2012 .

An overview of current and emerging SERMs

B. Komm, S. Mirkin, 2014, The Journal of Steroid Biochemistry and Molecular Biology.

Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data

Hugo A. Wefer, Melis N. Anahtar, R. J. Hayes, 2022, BMC Medicine.

Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement tools.

L. Dennerstein, T. Symonds, J. Simon, 2014, Maturitas.

A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture

Jacques P. Brown, S. Silverman, A. Chines, 2015, Menopause.

Human vaginal pH and microbiota: an update

D. Archer, S. Mirkin, Keshav Godha, 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

The utility of measuring anti-Müllerian hormone in predicting menopause

S. Mirkin, B. Aydogan, 2015, Climacteric : the journal of the International Menopause Society.

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

G. Constantine, R. Kagan, D. Archer, 2018, Obstetrics and gynecology.

A Pooled Analysis of the Effects of Conjugated Estrogens/Bazedoxifene on Lipid Parameters in Postmenopausal Women From the Selective Estrogens, Menopause, and Response to Therapy (SMART) Trials.

A. Chines, K. Ryan, K. Pan, 2015, The Journal of clinical endocrinology and metabolism.

Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies

C. Azen, F. Stanczyk, S. Mirkin, 2019, Menopause.

Selective estrogen receptor modulators (SERMs): a review of clinical data.

S. Mirkin, J. Pickar, 2015, Maturitas.

Evolution of the tissue selective estrogen complex (TSEC)

B. Komm, S. Mirkin, 2013, Journal of cellular physiology.